Early onset neonatal sepsis due to Group B streptococci (GBS) is responsible for severe morbidity and mortality of newborns. While different preventive strategies to identify women at risk are being recommended, the optimal strategy depends on the incidence of GBS-sepsis and on the prevalence of anogenital GBS colonization. We therefore aimed to assess the Group B streptococci prevalence and its consequences on different prevention strategies.
Introduction
Intrapartum vaginal presence of Group B Streptococcus (Streptococcus agalactiae, GBS), a facultative gram-positive diplococcus, can cause severe neonatal infections including sepsis, pneumonia and meningitis, which generally occur within the first week of life (early-onset disease) or after seven days (late-onset disease) w6, 15x. Infections with GBS have been recognized as the leading cause of early-onset neonatal sepsis with significant mortality. Epidemiologic studies in the pre-prevention era revealed an incidence of 1-3 cases of early-onset neonatal GBS per 1000 with a case-fatality rate of 20-50% w22, 28x. The risk of colonization of a neonate born to a colonized mother is between 40 and 70% w5, 10, 13x and 1-2% of these colonized infants will develop an earlyonset disease. At any given time, between 10-30% of women in the United States and between 5-15% in Europe are colonized with GBS w24, 26, 27x. Thus, in the 1980s intensive research started with the goal to find a way of preventing GBSs vertical transmission. Randomized controlled trials showed that intrapartum antibiotic treatment of colonized women prevents early-onset neonatal sepsis with 80% effectiveness w8x. However, because no rapid GBS detection test with a high sensitivity and specificity exists to date, it was a matter of debate how to identify women who benefit from intrapartum antibiotic prophylaxis. Guidelines for intrapartum prophylaxis of neonatal GBS infections were issued in 1996 by the American College of Obstetricians and Gynecologists (ACOG) and the centers of disease control (CDC) w4x, and in 1997 by the American Academy of Pediatrics (AAP) w1x.
These recommendations were that intrapartum antibiotic prophylaxis is given based either on a risk-or on a screening-based approach. A risk-based approach is adapted from the presence of at least one maternal risk factor. Risk-factors associated with neonatal GBS disease are: gestational age at delivery -37 weeks, intrapartum temperature G388C (100.48F), rupture of membranes for G18 h (G12 h), GBS bacteriuria during the current pregnancy or a previous delivery of a child affected by early-onset GBS sepsis. The screeningbased approach includes universal screening of all pregnant women for GBS colonization between 35 and 37 weeks' gestation and offering intrapartum antibiotics to all colonized women irrespective of other risk factors except GBS bacteruria during their current pregnancy, or a previous birth of an infant affected by early-onset GBS disease. An alternative strategy, which aims to reduce the number of women receiving intrapartum antibiotics by combining these two strategies, was also recommended by the Canadian Task Force Committee w23x. Only women screened positive for GBS and having one of the above-mentioned intrapartum risk factors receive prophylaxis with antibiotics during labor. In a previous study, we showed the efficacy of such a strategy w19x.
In 2002 these guidelines were revised by the CDC, AAP and ACOG due to new data showing superior effectiveness of the screening-based strategy w21x. The German Association for Gynecology and Obstetrics (DGGG) w16x and the Swiss Society for Gynecology and Obstetrics (SGGG) w25x adopted these suggestions, whereas the British Royal College of Obstetricians and Gynaecologists (RCOG) rejected it due to increased costs, potential increase in penicillin-induced anaphylaxis and microbial resistance w14x.
In order to achieve the optimal strategy in a population, updated epidemiological data about the prevalence of GBS carriers, about the intrapartum risk-profile of women, and also about the incidence of early-onset GBSsepsis are required. Based on the social, economical and local settings, results from these surveys differ to a significant extent. The purpose of this study was therefore to establish a detailed epidemiological dataset within our own population with respect to GBS carrier status, risk factors during birth and direct costs of different prevention strategies. In the future these data might be used as a historic control group after potential improvements in the diagnostic and/or therapeutic procedure.
Material and methods
We analyzed 1316 pregnant women in order to detect the prevalence of GBS colonization during pregnancy and the prevalence of intrapartum risk factors in GBS-colonized women between March 2005 and September 2006 at the University Women's Hospital Bern, Switzerland.
All pregnant women, who were screened for GBS during this time period (ns1327) were included. Swabs were taken from the outer third of the vagina and the anal region, and analyzed by standard as well as selective bacterial cultures. Clinical data regarding risk factors were obtained from the patients charts. The patients' records of those who had a positive culture result were evaluated and the following variables noted: week of gestation at latest screening, method of delivery (spontaneous, vaginal-operative delivery, elective or secondary cesarean section), intrapartum risk factors, intrapartum antibiotic prophylaxis (IAP), and allergy reactions. Intrapartum risk factor are defined as prolonged ROM ()18 h), preterm delivery (-37 weeks' gestation) and maternal intrapartum fever (388C or )100.38F). Furthermore, GBS bacteruria during pregnancy and birth of a previous infant with GBS sepsis were recorded as risk factors. The illustration of risk factors and IAP comprises all women, who delivered spontaneously, by vaginal-operative delivery or secondary cesarean section (ns163); women with elective cesarean section were excluded because there is uniform consensus that these women do not need GBS-prophylaxis due to an extremely low vertical transmission rate of GBS.
According to the CDC and ACOG guidelines, swabs were taken from both the vagina and the anal region and cultured in selective Todd-Hewitt broth supplemented with Nalixid acid and Colistin. The inoculated selective medium is incubated for 18-24 h and then subcultured onto sheep blood agar. Suspected colonies were tested by the CAMP assay. The sensitivity of the antenatal standard direct blood agar was defined as the proportion of women with positive GBS cultures in this standard culturing whose selective broth cultures were positive.
Finally, a cost analysis of antibiotic prophylaxis during birth was conducted. The cost of negative GBS culture, including material and staff time was estimated at 31 CHF. Due to additional tests, a positive culture was estimated at 72 CHF. The administration of intrapartum antibiotic prophylaxis was estimated at an average cost of 110 CHF, which includes two doses of antibiotics, the infusion device, intravenous fluids, and the cost of 30 min of a midwife's time. The cost-analyses of three different treatment strategies with intrapartum antibiotic prophylaxis were compared: (1) A risk-based strategy with administration of IAP only in presence of intrapartum risk factors. (2) A screening-based strategy with culture taken at 35-37 weeks of gestation and IAP given to all colonized women. (3) A combined screening/risk based strategy consisting of culture taken at 35-37 weeks of gestation and IAP only for GBS colonized women who, in addition, present at least one intrapartum risk factor.
Results
During the period between March 1, 2005 and September 30, 2006, 1316 pregnant women were screened for GBS by selective enrichment broth of rectovaginal swabs. A total of 1040 (79%) patients had a negative culture result and in 276 (21%) cases GBS carrier state was detected by selective enrichment broth.
At our institution, 201 pregnant women with positive culture results gave birth to an infant during this time period; in 75 cases patients attended our institution for a one-time emergency visit. In these cases follow-up and delivery was supervised by the patient's primary obstetrician. Of those who delivered at our institution, 163 (81%) delivered spontaneously, by vaginal operation or by secondary cesarean section. In 102 (62%) of these women, no intrapartum risk factor was identified, in 61 (37%) at least one risk factor at birth had been identified (no risk factor known: ns102 (62%); 1 risk factor known: ns43 (26%), 2 risk factors known: ns16 (10%), 3 risk factors known: ns2 (1%), F1 risk factor known: 61 (37%) (Table 1A) .
Thus, pursuing a risk-based policy, 61 women out of the 163 colonized women with spontaneous, operative vaginal or non-elective cesarean delivery would have received IAP. Reviewing all intrapartum risk factors of these women in detail, 20% (ns32) of these women had ROM )18 h, 3% (ns3) temperature )388C, 22% (ns36) delivered prior to maturity, in 7% (ns12) GBS bacteruria during pregnancy was found and birth of previous neonate had been known in one case (Table 1B) . Some institutions include ROM )12 h instead of ROM )18 h as a risk factor. Evaluating this in the overall risk-based analysis, no significant difference was found considering ROM )12 h (62 women, 38%, had at least one risk factor) compared to ROM )18 h (61 women, 37%, had at least one risk factor).
At our institution, a screening-based strategy is implemented, including IAP to all colonized women. As mentioned above, in 163 women with spontaneous, vaginal operative or secondary cesarean delivery, GBS-carrier state was verified. At the time of delivery, in 152 cases the culture result was actually known. In the remaining 11 cases, the culture result was available only after birth. One hundred and forty-five of these women received IAP (penicillin-based: ns128 women; clindamycin: ns8 women; erythromycin: ns9 women). Seven women did not receive any IAP for the following reasons: three women arrived at the hospital and delivered within one hour before antibiotics could be effectively given, two women had a subsequent negative GBS culture and for two women no reason for lack of IAP could be found.
Between the period of March 2005 until September 2006 one pregnant woman with verified GBS-colonization gave birth to a neonate affected by early-onset GBS-sepsis. This woman underwent a secondary cesarean delivery due to premature rupture of membranes )18 h at 32nd week of gestation. Following hospitalization IAP with erythromycin due to penicillin-allergy was given. The GBS showed sensitivity to erythromycin in antibiotic resistance tests.
In 12 of 163 women (7.4%), that delivered either spontaneously, by vaginal operation or by secondary cesarean section, allergy to penicillin was known. These women received erythromycin or clindamycin as IAP. No women developed anaphylaxis.
In Table 2 , the calculation of direct costs on a cohort of 1000 pregnant women is shown. By implementation of a risk-based strategy, the cost of GBS prevention has been calculated (see Table 2 ) estimated at 18,500 CHF/ 1000 live birth, by a screening-based approach as high as 50,108 CHF/1000 live birth and by a mixed screening and risk-based as high as 43,493 CHF/1000 live birth. The treatment costs of neonatal GBS disease not prevented by the respective strategies were not included in this analysis.
Discussion
Since the 1970s, GBS is increasingly recognized as a leading cause of serious neonatal infection with high morbidity and mortality. Consequently, prevention strat- (ns210) with G1 risk factor ™8,470 CHF egies were developed and analyzed. Three main approaches have been adopted: a screening-based strategy, a risk-based strategy and a combination of both. These strategies effectively prevent early-onset GBS disease in newborns w8, 22, 27x: an active, populationbased surveillance of the USA indicated a decline of the incidence of neonatal GBS sepsis by 70% from 1.7 to 0.5 cases per 1000 live births from 1989 to 1999 w21, 22x. However, disadvantages including costs, potential penicillin-induced anaphylaxis, and selection of resistant bacterial strains in newborns have led to controversies about the optimal preventive strategy w12, 21x. The RCOG guidelines, for example, do not recommend universal screening due to suboptimal cost-effectiveness ratio, lack of evidence of superiority of screening from randomized controlled trials, and a low incidence of GBS sepsis in the UK without screening (0.5 per 1000 newborns). Interestingly, GBS carrier data in pregnant women in the UK, which were cited in the guideline, originate from a study as old as 20 years. These recommendations have recently been challenged by a novel cost-effectiveness analysis in the UK w9x. The universal screening and IAP strategy has meanwhile been shown to be superior regarding early-onset neonatal GBS disease prevention as compared to the risk-based approach w21x: A 100% implementation of a risk-based prevention strategy would have reduced the incidence from 0.5/1000 to 0.44/ 1000 live births whereas a 100% implementation of a screening-based strategy would have led to a further reduction to 0.32/1000 live births w21x.
Thus, in 2002 the CDC revised their guidelines preferring a screening-based approach, which has been also adopted by the German societies for Obstetrics and Gynecology. Considering the notable increase in the proportion of women receiving antibiotics in labor with elevated risk of anaphylaxis and of bacterial resistance, the implementation of either preventive strategy might or might not be justified depending on the prevalence of maternal colonization, the intrapartum risk-profile and on the incidence of early-onset GBS disease w24x as well as on the cost profile.
The results from our population show that GBS colonization in pregnancy is observed with a prevalence of 21%. In the US, prevalence of maternal colonization ranges from 10-30% and in most European countries from 10-20% w27x. Other data from Switzerland report a prevalence of GBS colonization of 7.8% in Geneva w24x and 10% in Basel w26x. This lower prevalence may be due to regional differences or from different sampling or culturing techniques (vaginal samples alone or standard non-selective culture techniques yield a lower prevalence). Before the widespread use of IAP, the incidence of neonatal GBS disease in the US ranged from 2-3 cases per 1000 live births w7, 28x. In Europe, earlyonset GBS sepsis develops in 0.3-2/1000 (N); Swiss data report an incidence from 0.4/1000 live births in Geneva w24x and 1/1000 in Basel w26x, whereas at the University of Berne an incidence of 1.2/1000 has been recorded, concordant with a higher GBS colonization in pregnancy in Berne.
Our study further shows the risk profile of each woman with positive screening culture result. In 37% (ns61) of cases the women presented at least one intrapartum risk factor whereas no risk factor was recognized in 63% (ns102) of positive tested women. Thus, following a riskbased approach as many as 63% (ns102) of colonized women were neglected in receiving IAP and only 37% of colonized women would have received intrapartum antibiotic prophylaxis. Therefore, risk-based IAP will not cover all colonized women and there will be more cases of early-onset disease considering that 40-70% newborns of colonized women are also infected with GBS and 1% of these colonized neonatal develop neonatal GBS sepsis w7, 10, 13x.
As compared to other published studies, the prevalence of risk factors in our population is clearly higher than the 18-20% cited in other studies, indicating a risk profile typical for a tertiary care referral center (e.g., preterm delivery proportion of 22%). Following the riskbased strategy in our population, more women would receive antibiotics for risk factors that might not be caused by GBS in every case. Due to uncertain GBS status the risk-based strategy does not follow exact administration of IAP yielding a higher risk of allergic reactions, antibiotic resistance and other complications whereas a screening-based strategy is much more reliable.
Nevertheless, the screening-based strategy shows slightly higher costs than the risk-based approach. Relating to 1000 women costs of a screening-based implementation are CHF 62,710, whereas costs in a risk-based program add up to CHF 40,700. However, these calculations do not include treatment costs for newborn sepsis. To evaluate the screening program in terms of the total socio-economic burden, these consequential costs related to the treatment and care of septic newborns have to be balanced against the increased costs for the screening program. Prevention of a single case of newborn sepsis may, aside from the medical and ethical benefit, save easily the amount of money to compensate for the increased screening expenses for several thousands of women. Implementation of a risk-based IAP will not cover all colonized women and there will be more cases of early-onset disease. Besides, more women will receive antibiotics for risk factors that might not be caused by GBS. Thus, higher risk for bacterial resistance and anaphylactic reactions might be found, which may also result in higher cost.
In the future, the implementation of a rapid PCR-based intrapartum screening might improve sensitivity and specificity of GBS-screening at time of delivery and, therefore, increase effectiveness of the screening-based strategy w11, 18x. Furthermore, an effective GBS vaccination is expected to be available in 5-10 years which is likely to replace all other preventive strategies.
In conclusion, a screening-based strategy should be favored despite higher costs in first place. In the future, cheaper and more rapid testing should be developed. Generally, an intrapartum antibiotic prophylaxis is justified concerning a prevalence rate of 21% and an incidence of early-onset disease of 1.2/1000 live births.
